[Corrigendum] Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway
Affiliations: Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Neurosurgery, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
- Published online on: May 23, 2022 https://doi.org/10.3892/or.2022.8337
- Article Number: 126
Copyright : © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 40: [Related article:] 3285–3296, 2018; DOI: 10.3892/or.2018.6744
Following the publication of the above paper, during a routine examination of the raw data the authors noticed errors in Fig. 5 in the published version of the article. Essentially, in Fig. 5A on p. 3291, the western blot data for MMP2 (for the U87 cell line) did not match with the original data: An image from Fig. 7A (the western blotting data for Bcl2 in the U87 cell line had been erroneously selected during the process of assembling the figure); however, the authors were able to locate the original western blot data for MMP2 pertaining to Fig. 5A, and the corrected version of Fig. 5 is shown below.
RNF138 regulates the protein levels of HIF-1α, VEGF and MMP2 in glioma cell lines. (A) Western blotting analysis of HIF-1α, VEGF and MMP2 expression in U87 and U251 cells, β-actin was used as a loading control. Densitometry analysis of (B) HIF-1α, (C) VEGF and (D) MMP2 expression in U87 and U251 cells using ImageJ analysis. Data are presented as the mean ± standard deviation for three independent experiments. **P<0.01. RNF138, ring finger protein 138; siRNA, small interfering RNA; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; MMP2, matrix metalloproteinase 2.
Note that these errors did not affect the overall conclusions reported in the study. All the authors agree to the publication of this corrigendum, and are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish it; furthermore, they apologize for any inconvenience caused to the readership of the Journal.